Prevail Therapeutics Inc. announced the appointment of Morgan Sheng, Ph.D., to its Board of Directors. Dr. Sheng is a Core Institute Member and Co-Director of the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard. He is also a Professor in the Department of Brain and Cognitive Science at MIT. Previously, he was Vice President of Neuroscience at Genentech, where he was head of neuroscience research and drug discovery. Under his leadership at Genentech, multiple innovative programs for treatment of serious diseases of the nervous system advanced into clinical trials. Prior to joining Genentech, Dr. Sheng was the Menicon Professor of Neuroscience at MIT, as well as an Investigator of the Howard Hughes Medical Institute. He is a Fellow of the Royal Society in the U.K., the Academy of Medical Sciences in the U.K. and the American Association for the Advancement of Science and is the author of more than 200 peer-reviewed publications focused on the molecular cellular biology of brain synapses and the mechanisms of neurodegenerative diseases. Dr. Sheng holds a Ph.D. in molecular genetics from Harvard University, a B.A. from Oxford University, and obtained his medical degree and training in internal medicine at London University. Following his postdoctoral work in neuroscience at the University of California, San Francisco, he served on the faculty at Massachusetts General Hospital and Harvard Medical School before joining MIT.